论文部分内容阅读
本文推荐了Soulier等对70例PHC患者进行的去γ碳氧凝血酶元(des-r-carboxyprothrombin,简称DCP)的检测.DCP为凝血酶元的前体,系在正常肝内合成的一种依赖维生素K的血凝蛋白,而其谷氨酸的残基需羧基化后才能转化为有活力的凝血酶元.原发性肝癌细胞亦能合成此种蛋白,但与正常肝细胞不同者在于恶性细胞不能使其谷氨酸残基羧化,因此即使在维生素K的条件下亦不能转化为有活力的凝血酶元,故据Soulier等所检测的70例PHC患者中,血清DCP增高的阳性率为74%,而15例较移性肝癌患者仅1例增高,慢性肝炎或肝硬化患者均不增高.当与AFP共同检测时PHC的阳性率可达87%.作者进一步提出:单独检测上述血清肿瘤标志物是否足够?目前已知有症状的PHC患者,血清AFP正
In this review, Soulier et al. [1] examined the detection of des-r-carboxyprothrombin (DCP) in 70 patients with PHC, a precursor of thrombin, a Dependent on vitamin K hemagglutinin, and its glutamic acid residue after carboxylation before it can be transformed into a viable thrombin element. Primary liver cancer cells can synthesize this protein, but different from normal liver cells is that Malignant cells are unable to carboxylate their glutamic acid residues and therefore can not be converted to viable thrombin even under vitamin K conditions. Therefore, among the 70 patients with PHC detected by Soulier et al, the elevated positive serum DCP Rate was 74%, while 15 cases of patients with more advanced liver cancer increased in only 1 case, patients with chronic hepatitis or cirrhosis were not increased when tested together with AFP PHC positive rate of up to 87%. The authors further proposed: Serum tumor markers are sufficient? Currently known symptoms of PHC patients, serum AFP positive